Cardiff Oncology vs Silence Therapeutics
Cardiff Oncology reported revenue of $1 million in fiscal 2025, about the same as Silence Therapeutics' $1 million in fiscal 2025. Cardiff Oncology's revenue fell 13.2% in its latest year, and Silence Therapeutics' fell 98.7%. Cardiff Oncology had an operating margin of -8256.3%, against -16292.8% at Silence Therapeutics. Free cash flow was −$38 million at Cardiff Oncology and −$62 million at Silence Therapeutics.
Side by side
| Cardiff Oncology | Silence Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1M | $1M |
| Revenue growth | −13.2% | −98.7% |
| Revenue growth a year, last 5 years | 8.4% | — |
| Gross margin | — | 61.5% |
| Operating margin | −8,256.3% | −16,292.8% |
| Net margin | −7,732.0% | −15,851.9% |
| Free cash flow | −$38M | −$62M |
| Free cash flow margin | −6,402.5% | −11,149.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 40.3% | 2.1% |
| Last close | $0.89 | $19.81 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $1.1 million, sold $0 | — |
| Piotroski F-score | 2 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Cardiff OncologySilence Therapeutics
Operating margin
Percent of revenue
Cardiff OncologySilence Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cardiff OncologySilence Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cardiff Oncology and Silence Therapeutics pages.